Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
The pentetreotide peptide moiety binds somatostatin receptors, particularly subtype 2, expressed on many neuroendocrine tumour cells. When conjugated with indium-111, the radiolabel enables scintigraphic localisation of somatostatin-receptor-positive lesions.
Indications / reported uses
Used as the peptide component of indium In-111 pentetreotide (octreotide DTPA) for scintigraphic imaging of somatostatin-receptor-positive neuroendocrine tumours; the radiolabelled product, not unlabelled pentetreotide alone, is the diagnostic radiopharmaceutical.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pentetreotide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pentetreotide Permitted Daily Exposure (PDE) report (the Pentetreotide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pentetreotide Occupational Exposure Limit (OEL) report (the Pentetreotide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.